MétaCan
Menu
Back to cohort

Distinguishing aggressive versus nonaggressive prostate cancer using a novel prognostic proteomics biopsy test, ProMark.

2014· article· en· W2624981566 on OpenAlexaff
Fred Saad, Michail Shipitsin, Sibgat Choudhury, Teresa Capela, Christina Ernst, Aeron Hurley, Clayton Small, Alexander Kaprelyants, Sadiq Hussain, Hua Chang, Eldar Giladi, James Dunyak, Louis Coupal, Thomas P. Nifong, Mathieu Latour, David M. Berman, Peter Blume‐Jensen

Bibliographic record

VenueJournal of Clinical Oncology · 2014
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer, Lipids, and Metabolism
Canadian institutionsQueen's UniversityCentre Hospitalier de l’Université de MontréalImpactUniversité de Montréal
Fundersnot available
KeywordsMedicineProstate cancerOncologyCancerProteomicsBiopsyInternal medicine

Abstract

fetched live from OpenAlex

5090 Background: Current clinical and pathological parameters are insufficient for accurate prediction of progression risk for patients with biopsy Gleason grades 3+3 or 3+4. Reasons for this include biopsy sampling error and pathologist grading discordance, resulting in inaccurate prostate pathology assessment. Consequently, a majority of these patients are over-treated. We have established a novel proteomics-based test, ProMark for automated quantitative measurements of biomarkers from tumor epithelium of intact FFPE biopsy tissue. The test generates a personalized risk score predictive of prostate tumor pathology at the time of biopsy. Methods: A clinical biopsy simulation study using prostatectomy tissue (N=380) was designed to identify 12 biomarkers that can predict surgical Gleason score and lethal disease despite sampling error. Next, a clinical study of 381 biopsies with matched prostatectomy annotation was done to select the best marker subset predictive of prostate pathology. Subsequently, the locked model was validated in a separate blinded clinical study with centralized Gleason grading (N=274). Results: The Promark risk scores were strongly predictive of prostate tumor pathology, the primary study objective. The test was able to separate ‘favorable’ cases [surgical Gleason score 3+3 or 3+4; organ-confined (<=pT2)] from ‘non-favorable’ cases [non-organ-confined disease (≥T3a, N, or M) or surgical Gleason >=4+3] with an AUC of 0.68 (0.61-0.74;p<0.0001). At risk score <0.33 the specificity for prediction of favorable disease is 90% with a predictive value of 81%. At a risk score > 0.8, the predictive value for non-favorable disease is 77%. Importantly, ProMark provides improved personalized disease prediction relative to standard risk stratification systems, including NCCN and D’Amico. Conclusions: We have established a novel prognostic test, ProMark, for prostate cancer biopsies. The risk scores are generated independent of clinical and pathological parameters and correlate strongly with pathological outcome. The test could be useful as an aid in clinical decision making for stratification of patients into good and poor candidates for active surveillance.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.000
Insufficient payload (model declined to judge)0.0010.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.075
GPT teacher head0.423
Teacher spread0.348 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicCancer, Lipids, and MetabolismFrench-language works237,207